Skip to main content
OpenTrials
Completed

NCT Number: NCT07560059

Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)

Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after hospital discharge.

The DMD-COV study is a prospective, multicenter observational cohort conducted in Algeria. Its aim is to evaluate the cardio-metabolic outcomes of adult patients with diabetes who were hospitalized for confirmed COVID-19 and survived the acute phase of the infection.

Adult patients with type 1 or type 2 diabetes will be included during hospitalization or within 30 days after hospital discharge. Participants will be followed for up to one year after discharge, with scheduled evaluations at baseline, 3 months, 6 months, and 12 months.

During follow-up, clinical, biological, and therapeutic data will be collected, including glycemic control (HbA1c), body weight, lipid profile, kidney function, and diabetes treatments. The main outcome is the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization for COVID-19.

The results of this study will help to better understand the long-term metabolic impact of COVID-19 in people with diabetes and to improve post-COVID diabetes management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Disease Attributes Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Infections Insulin Resistance Lung Diseases Metabolic Diseases Metabolic Syndrome Nidovirales Infections Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Post-Acute COVID-19 Syndrome Post-Infectious Disorders RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Djillali Belkhenchir Public Hospital (formerly Birtraria)

Algiers, El Biar, Algeria

About this study

The DMD-COV study is a prospective, non-interventional, multicenter cohort study conducted in Algeria. The study aims to describe the cardio-metabolic outcomes of adult patients with diabetes following hospitalization for COVID-19.

Patients with type 1 or type 2 diabetes who were hospitalized for laboratory-confirmed COVID-19 (PCR, serology, or antigen test) will be included during hospitalization or within 30 days after discharge. The study does not interfere with routine clinical care, and all therapeutic decisions are made according to usual medical practice.

Approximately 200 patients will be enrolled across multiple university hospital centers. Participants will be followed for one year, with four scheduled visits: at baseline (inclusion), 3 months, 6 months, and 12 months after hospital discharge.

Data collected during the study include demographic characteristics, diabetes history, comorbidities, COVID-19 severity markers, duration of hospitalization, and treatments received during the acute phase, including corticosteroids and anticoagulants. At each follow-up visit, clinical parameters (weight, body mass index, waist circumference), glycemic control (HbA1c, fasting plasma glucose), lipid profile, renal function, and diabetes treatments will be recorded.

The primary outcome is glycemic control, assessed by the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization. Secondary outcomes include changes in HbA1c over time, evolution of diabetes treatments, weight changes, lipid profile, renal function, and identification of factors associated with good glycemic control after COVID-19.

This study will provide valuable real-world data on the metabolic evolution of patients with diabetes after COVID-19 and may contribute to optimizing long-term follow-up strategies in this population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of type 1 or type 2 diabetes mellitus
  • Hospitalization for laboratory-confirmed COVID-19
  • Inclusion during hospitalization or within 30 days after hospital discharge
  • Signed informed consent

Exclusion criteria

  • Age under 18 years
  • Absence of diabetes mellitus
  • Refusal or inability to provide informed consent

Treatment and study plan

No intervention (observational study)

Other

This is a non-interventional observational study. No experimental or therapeutic intervention is assigned as part of the study protocol. All medical care and treatments are provided according to routine clinical practice.

Primary outcomes

  1. Glycemic control after hospitalization for COVID-19

    Time frame: 6 months and 12 months after hospital discharge

    Proportion of patients achieving their individualized HbA1c target according to international diabetes guidelines.

Secondary outcomes

  1. Change in HbA1c over follow-up

    Time frame: Baseline, 3 months, 6 months, and 12 months

    Mean change in HbA1c from baseline to 3 months, 6 months, and 12 months after hospital discharge.

  2. Change in body weight and body mass index

    Time frame: Baseline, 3 months, 6 months, and 12 months

    Change in body weight and body mass index (BMI) during follow-up.

  3. Evolution of diabetes treatment

    Time frame: Up to 12 months after hospital discharge

    Changes in diabetes treatment regimen during follow-up, including insulin initiation or intensification and modification of oral or injectable antidiabetic therapies.

  4. Changes in lipid profile and renal function

    Time frame: Baseline, 6 months, and 12 months

    Changes in lipid profile parameters and renal function during follow-up after COVID-19 hospitalization.

  5. Factors associated with poor glycemic control after COVID-19

    Time frame: Up to 12 months after hospital discharge

    Identification of clinical and therapeutic factors associated with failure to achieve individualized HbA1c targets after hospitalization for COVID-19.

Sponsors and collaborators

Lead sponsor

Algerian Society of Diabetology

Other

Collaborators

  • Algerian Society of Internal Medicine
  • Novo Nordisk A/S

Registry information

Official study title

Acute Metabolic Outcomes of Diabetic Patients Hospitalized for COVID-19 in Algeria: A Prospective Cohort Study (DMD-COV)

Acronym: DMD-COV

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 30, 2026
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.